INmune Bio Inc. (INMB)
| Market Cap | 46.26M -40.2% |
| Revenue (ttm) | n/a +257.1% |
| Net Income | -41.60M |
| EPS | -1.61 |
| Shares Out | 26.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,114 |
| Open | 1.700 |
| Previous Close | 1.690 |
| Day's Range | 1.690 - 1.770 |
| 52-Week Range | 1.090 - 3.190 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+302.28%) |
| Earnings Date | Aug 6, 2026 |
About INMB
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatmen... [Read more]
Financial Performance
In 2025, INmune Bio's revenue was $50,000, an increase of 257.14% compared to the previous year's $14,000. Losses were -$45.93 million, 9.15% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for INMB stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 302.28% from the latest price.
News
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities
INmune Bio processes first umbilical cord tissue at CGT Catapult
INmune Bio (INMB) announced the company has successfully processed its first commercial-ready umbilical cord tissue at the Cell and Gene Therapy Catapult Manufacturing Innovation Centre in Stevenage, ...
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Dis...
INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
The study points to soluble TNF as a key biological link between head injury and Alzheimer's disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloi...
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.
INmune Bio advances CORDStrom platform patent application in the U.S.
INmune Bio (INMB) announced that it has submitted its CORDStrom platform patent application into the U.S. national phase before the United States Patent and Trademark Office, or USPTO. Published first...
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045
INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan
INmune Bio (INMB) announced that the UK Medicines & Healthcare products Regulatory Agency, or MHRA, has approved the pediatric investigation plan, or PIP, for Ebstrocel for the treatment of Recessive…
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United Kingdom
INmune Bio announces MHRA alignment in pre-MAA CORDStrom meeting
INmune Bio (INMB) announced that it has received official, accepted meeting minutes from its recent face-to-face pre-Marketing Authorization Application, or pre-MAA, Scientific Advice meeting with the...
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packages MHRA pediatric feedback recognizes Mission...
INmune Bio Transcript: AGM 2026
The meeting addressed board elections, auditor ratification, and an amended stock incentive plan, all of which were approved by stockholders. A quorum was present, and final voting results will be filed with the SEC. Stockholders participated in a Q&A session.
INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial
INmune Bio (INMB) announced positive results from exploratory MRI imaging analyses of its MINDFuL Phase 2 trial of XPro in patients with early Alzheimer’s disease. “A statistically significant treatme...
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.
INmune Bio Slides: Corporate presentation
INmune Bio has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
INmune Bio publishes MINDFuL trial results in NPJ Dementia
INmune Bio (INMB) announced that results from its Phase 2 MINDFuL trial in Alzheimer’s disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker…
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that...
INmune Bio receives fast track designation from FDA for XPro
INmune Bio (INMB) announced that the FDA has granted fast track designation to XPro, the company’s selective soluble TNF inhibitor, for the treatment of early Alzheimer’s disease. The designation spec...
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug ...
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- INmune Bio, a clinical-stage biotechnol...
INmune Bio Earnings Call Transcript: Q1 2026
Q1 2026 saw reduced net loss and R&D expenses, with $21.4M in cash supporting operations into 2027. Regulatory and manufacturing milestones for CORDStrom are progressing, while XPro advances with new imaging data and partnership exploration.
INmune Bio Earnings release: Q1 2026
INmune Bio released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
INmune Bio Quarterly report: Q1 2026
INmune Bio has published its Q1 2026 quarterly earnings report on May 7, 2026.
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
BOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's inna...
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
LONDON, UK and BOCA RATON, FL, May 05, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune Bio”), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity ...